Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Objective There is no standardized approach to the treatment of pediatric antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Because of the rarity of pediatric AAV, randomized trials have not been feasible. The present study of the Childhood Arthritis and Rheumatology Research Alliance...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis care & research (2010) 2022-09, Vol.74 (9), p.1550-1558
Main Authors: Morishita, Kimberly A., Wagner‐Weiner, Linda, Yen, Eric Y., Sivaraman, Vidya, James, Karen E., Gerstbacher, Dana, Szymanski, Ann M., O'Neil, Kathleen M., Cabral, David A.
Format: Article
Language:English
Subjects:
Antineutrophil cytoplasmic antibodies
Arthritis
Children
Clinical trials
Glucocorticoids
Granulomatosis
Leukocytes (eosinophilic)
Literature reviews
Pediatrics
Remission
Rheumatology
Vasculitis
Weaning
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective There is no standardized approach to the treatment of pediatric antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Because of the rarity of pediatric AAV, randomized trials have not been feasible. The present study of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) was undertaken to establish consensus treatment plans (CTPs) for severe pediatric AAV to enable the future study of comparative effectiveness and safety. Methods A workgroup of CARRA members (rheumatologists and nephrologists) formed the AAV Workgroup. This group performed a literature review on existing evidence‐based treatments and guidelines for the management of AAV. They determined that the target population for CTP development was patients
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.24590